High-dose chemotherapy sensitizes locally advanced esophageal squamous cell carcinoma to PD-1 blockade for a higher pathological complete response rate and survival-Reference-Cited by-同舟云学术

High-dose chemotherapy sensitizes locally advanced esophageal squamous cell carcinoma to PD-1 blockade for a higher pathological complete response rate and survival

Published:2023-10 Issue: Volume:36 Page:101736
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Wang Peiyuan,Lei Mengxia,Weng Guibin,Huang Rongfang,Lin Hui,Wei Wenwei,Chen Yujie,He Hao,Chen Peng,Zhang Derong,Chen Weijie,Zhou Hang,Gao Pengqiang,Liu Shuoyan^ORCID,Wang Feng

Funder

Science and Technology Program of Hunan Province

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference35 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021

2. Epidemiology of Esophageal Squamous Cell Carcinoma;Abnet;Gastroenterology,2018

3. Preoperative chemoradiotherapy for esophageal or junctional cancer;van Hagen;N. Engl. J. Med.,2012

4. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial;Yang;J. Clin. Oncol.,2018

5. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010;Liu;Eur. J. Cancer,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of PD-1 Monoclonal antibodies in the treatment of esophageal squamous cell carcinoma: Systematic review and meta Regression;Heliyon;2024-07

2. Comparison of Neoadjuvant Chemoimmunotherapy and Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Study with 3-Year Survival Analysis;2024-06-13